About the Company
atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LIFE News
Buy Rating Affirmed for aTyr Pharma as Lead Candidate efzofitimod Advances in Clinical Trials with Solid Financial Footing
Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on aTyr Pharma (LIFE – Research Report). The associated ...
Atyr Pharma: Q4 Earnings Snapshot
SAN DIEGO — SAN DIEGO — Atyr Pharma Inc. (LIFE) on Thursday reported a loss of $14.8 million in its fourth quarter. The San Diego-based company said it had a loss of 25 cents per share. Get a curated ...
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP ...
Q4 2023 aTyr Pharma Inc Earnings Call
Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or ...
aTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), ...
Atyr Pharma: Q4 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Atyr Pharma Inc. (LIFE) on Thursday reported a loss of $14.8 million in its fourth quarter. The San Diego-based company said it had a loss of 25 cents per share.
Loading the latest forecasts...